Full access to Entrepreneur for $5
Subscribe

Pfizer (PFE) Begins Study on RSV Vaccine in Older Adults

Pfizer (PFE) starts a phase III study which will evaluate its respiratory syncytial virus vaccine candidate, RSVpreF in adults aged 60 years and above...

By
This story originally appeared on Zacks

Pfizer Inc. PFE announced that it has initiated the phase III RENOIR study that will evaluate its respiratory syncytial virus (“RSV”) bivalent prefusion F subunit investigational vaccine candidate — RSVpreF — in older adults aged 60 years and above.

- Zacks

The double-blind, placebo-controlled RENOIR study will evaluate the safety, efficacy and immunogenicity of a single dose of RSVpreF for treating RSV in adults. Currently, there is no vaccine approved for treating RSV.

The company plans to enroll around 30,000 participants in the above-mentioned study. The primary goal of the study is to assess the safety and efficacy of RSVpreF for the prevention of moderate to severe lower respiratory tract illness during the first RSV season. Pfizer is also developing its maternal RSV vaccine candidate in late-stage studies.

Shares of Pfizer have rallied 27.3% so far this year compared with the industry’s rise of 15.1%.

Zacks Investment Research

Image Source: Zacks Investment Research

RSV is a common and pervasive cause of acute respiratory illness, which usually starts in the fall months. The highly contagious virus affects the lungs and airways.

Some other companies are also developing their respective vaccines for treating RSV.

British pharma giant Glaxo GSK is evaluating its maternal RSV vaccine candidate in the phase III GRACE study. The study will evaluate the efficacy of a single dose of the unadjuvanted candidate in pregnant women.

Glaxo is also developing RSV vaccines for pediatric patients as well as for older adults, using different novel technologies.

Small biotech firm Novavax NVAX is also developing ResVax, its RSV vaccine candidate, in a phase III study for protecting infants by immunizing their mothers against the disease. ResVax is also being investigated in phase II and phase I studies for addressing older adults and the pediatric patient population, respectively, for the given indication.

Zacks Rank & Stock to Consider

Pfizer currently carries a Zacks Rank #3 (Hold). A top-ranked stock in the biotech sector is Vertex Pharmaceuticals Incorporated VRTX, which has a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Vertex’s earnings estimates have been revised 10.4% upward for 2021 and 7.2% upward for 2022 over the past 60 days.



Tech IPOs With Massive Profit Potential: Last years top IPOs surged as much as 299% within the first two months. With record amounts of cash flooding into IPOs and a record-setting stock market, this year could be even more lucrative. 

See Zacks’ Hottest Tech IPOs Now >>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

GlaxoSmithKline plc (GSK): Free Stock Analysis Report

 

Pfizer Inc. (PFE): Free Stock Analysis Report

 

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

 

Novavax, Inc. (NVAX): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research